CHNXFCHITOGENX INC.

About CHITOGENX INC. (CHNXF)

CHITOGENX INC. (CHNXF) is a Biotechnology company headquartered in Kirkland, QC, Canada whose shares trade over-the-counter on the Pink tier.

ChitogenX Inc. is a clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various Regenerative Medicine Applications. Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about ChitogenX is available on the Company's website at www.chitogenx.com and on SEDAR at www.sedar.com.

Products and services

Ortho RTI is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Our proprietary RESTORE technology platform is a proprietary muco-adhesive Chitosan-based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. Ortho-R, our lead Chitosan-PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments.

CHNXF key facts

Ticker symbol

CHNXF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Kirkland, QC, Canada

Country of incorporation

CA

Year of incorporation

2015

Employees

1

Estimated market cap

$511.2K (as of May 9, 2025)

Shares outstanding

83,129,520

Reporting standard

International Reporting: Canadian Securities Exchange

Audit status

Audited

Fiscal year end

1/31

Latest filing

Interim Financial Report (Jul 31, 2024)

CHITOGENX INC. leadership

• Pierre Laurin — Interim CEO
• Luc Mainville — CFO
• Guy Paul Allard — VP, Legal, Corporate Secretary
• Sofia Parvin — Other, Legal Asst.
• Michael Shannon — Legal Counsel

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with C